HBHendrik Bonnemeier

Hendrik Bonnemeier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hendrik Bonnemeier has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antimicrobial Efficacy of a Taurolidine‐Based Antimicrobial Compound on Contaminated Surfaces Simulated in a Standardized 4‐Field Test

    by Benito Baldauf, Hendrik Bonnemeier, Ernest W. Lau, Jana Hummel, Reinhard Vonthein, Ojan Assadian

    Implantable medical devices, including cardiac electronic implants, joint prostheses, and breast implants, are essential to modern healthcare but remain susceptible to infection from microbial contamination during placement. Staphylococcus spp . and Candida albicans are the predominant pathogens, often causing severe complications, increased mortality, and substantial healthcare costs. With antibiotic resistance on the rise, intraoperative surface disinfection has emerged as a critical yet underutilized preventive strategy. Taurolidine, a broad‐spectrum antimicrobial with a strong safety profile and no known resistance, can be applied directly to both tissues and device surfaces. To replicate intraoperative decontamination, taurolidine‐saturated swabs are tested under standardized mechanical wiping using the European Norm EN 16615 “4‐field test.” The model reproduced short contact times and organic load conditions reflective of clinical practice, enabling assessment of both chemical and mechanical antimicrobial effects. Taurolidine achieved >5 log 10 reductions in Staphylococcus aureus , Pseudomonas aeruginosa , and Candida albicans , and >4 log 10 for Enterococcus hirae . The observed activity demonstrated a surface‐driven, enzyme‐independent mechanism involving spontaneous release of reactive N‐methylol functional groups that disrupt microbial membranes. Taurolidine's enzyme‐independent antimicrobial mechanism distinguishes it from solvent‐ or oxidant‐based disinfectants. These results support taurolidine as a potential adjunctive prophylactic agent to reduce device‐related infections during implantation procedures.


  • Open Access

    Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection

    by Stefan Borov, Benito Baldauf, Jana Henke, Herribert Pavaci, Arben Perani, Bernhard Zrenner, Josef Dietl, Julinda Mehilli, Ernest W Lau, Reinhard Vonthein, et al.

    TauroPace (Tauropharm, Bavaria Germany), a taurolidine solution for combating cardiac implantable electronic device (CIED) infection, was compared with a historical control of 3% hydrogen peroxide (H2O2) in a prospective observational study. The device pocket was irrigated, and all hardware accessible within (leads, suture sleeves, pulse generator) was wiped with H2O2, TauroPace, or taurolidine in a galenic formulation during any invasive CIED procedure at the study centre. Only CIED procedures covered by TauroPace or H2O2 from 1 January 2017 to 28 February 2022 were included for analysis. Patients who underwent >1 procedure were censored for the last treatment group and reassigned at the next procedure. The primary endpoint was major CIED infection within 3 months. The secondary endpoints were CIED infection beyond 3 months, adverse events potentially related to the antimicrobial solutions, CIED system, procedure, and death, till the end of follow-up. TauroPace covered 654 procedures on 631 patients, and H2O2 covered 551 procedures on 532 patients. The TauroPace group had more patient risk factors for infection than the H2O2 group (P = 0.0058) but similar device and procedure-specific risk factors (P = 0.17). Cardiac implantable electronic device infection occurred in 0/654 (0%) of the TauroPace group and 6/551 (1.1%) of the H2O2 group (P = 0.0075). Death occurred in 23/654 (3.5%) of the TauroPace group and 14/551 (2.5%) of the H2O2 group (P = 0.33). Non-infection related adverse events were rarer in the TauroPace (3.8%) than the H2O2 (6.0%) group (P = 0.0802). TauroPace is safe but more effective than H2O2 in reducing CIED infection. ClinicalTrials.gov Identifier: NCT05576194


  • AB12-1

    by Frank Eberhardt, Thorsten Hanke, Mathias Bechtel, Hendrik Bonnemeier, Uwe K.H. Wiegand, Martin Misfeld


  • Age Dependency of Sensing Performance and AV Synchrony in Single Lead VDD Pacing

    by Uwe K.H. Wiegand, Jürgen Potratz, Frank Bode, Regina Schneider, Werner Peters, Hendrik Bonnemeier, Hugo A. Katus

    Implantation of single lead VDD pacemakers is an established therapeutic option in patients with AV block and normal sinus node function. However, related to occurrence of sinus node disease and atrial undersensing, there is concern whether VDD devices are appropriate in physically active young patients. Two hundred thirty‐two consecutive patients with isolated A V block and VDD pacemakers were investigated. This population was subdivided into quartiles of 58 patients according to age at time of inclusion: 26.2–59.4 years (group A), 59.5–70.1 years (group B), 70.2–81.0 years (group C), and 81.1–92.5 years (group D). Follow‐up visits included pacemaker telemetry, Holier monitoring, and exercise testing. Patients were visited at 2 and 12 weeks after implantation thereafter followed by 6‐month intervals. Mean follow‐up period was 35 ± 14 months. Three months after implantation, atrial sensing threshold was significantly higher in young patients: 1.18 ± 0.58 mV (group A) versus 0.79 ± 0.35 mV (group B), 0.68 ± 0.33 mV (group C), and 0.60 ± 0.25 mV (group D), P < 0.001 for comparison of group A to all other groups. Atrial undersensing was observed less frequently in young patients: 6.9% (group A) versus 17.2% (group B), 24.1% (group C), and 27.6% (group D), P = 0.025 for intergroup comparisons. Sinus node dysfunction did not occur in group A. Atrial arrhythmias and loss of AV synchronized pacing mode occurred rarely in young patients: 0.6% (0.4%) per year in group A versus 1.3% (1.3%) in group B, 3.9% (3.4%) in group C, and 5.7% (7.4%) per year in group D, P < 0.01 for intergroup comparisons. Our data show good atrial sensing performance, low incidence of sinus node dysfunction, and few atrial arrhythmias in young patients with VDD pacing for AV block. Thus, single lead VDD pacing can be recommended particularly for young patients with AV block.